Cambridge Healthtech Institute第2届

Emerging Immuno-Oncology Targets

( 癌症免疫疗法的新标的 )

癌症免疫疗法与并用疗法的新标的与途径

2018年8月30日~31日

本单元以癌症免疫疗法的新标的为主题,具有免疫调节功能的抑制剂及拮抗标的、间质细胞与免疫细胞标的、免疫疗法的合理并用策略等各种与新标的相关的心议题将被提出,也将发表以发现及验证癌症免疫疗法新标的与并用疗法为目的的临床前研究与转译研究的个案发表。

Coverage will include, but is not limited to:

  • Emerging immunomodulatory targets
  • Checkpoint inhibitors (PD-1/PD-L1, CTLA-4, TIM3, LAG3)
  • Targeting agonist receptors (OX40, 4-1BB, GITR, CD27, ICOS, GITR)
  • Targeting tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs)
  • Targeting the STING pathway
  • Targeting CD96 and TIGIT for cancer immunotherapy
  • Targeting the stroma, tumor microenvironment
  • Targeting innate immunity
  • Rational combination immunotherapy

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English





免费电子邮件通知服务